Mobia Medical (NASDAQ:MOBI) reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded across new and existing stroke-care programs.
The company, which completed its initial public offering
